Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment. Originating from Dr. Engleman's lab at Stanford University, the company leverages groundbreaking technology to develop tumor-targeted therapies, capitalizing on the combined power of the innate and adaptive immune systems. Backed by top-tier life sciences investors, Bolt is on a promising growth trajectory, dedicated to bringing innovative and curative therapies to patients.
The company’s proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of its therapeutic pipeline, which includes candidates like BDC-1001 and BDC-3042. This platform merges tumor-targeting antibodies with immune-stimulating linker-payloads designed to reprogram the tumor microenvironment, fostering a robust anti-cancer response.
BDC-1001 targets HER2-positive cancers and has shown durable clinical responses and a favorable safety profile in Phase 1 trials. Notably, the FDA granted Orphan Drug Designation to BDC-1001 for gastric cancer treatment, underlining its potential to address unmet medical needs. Phase 2 trials are underway for various cancers, including breast, colorectal, and endometrial cancers.
BDC-3042 targets Dectin-2, a receptor expressed by tumor-associated macrophages (TAMs), and aims to convert these cells from tumor-supportive to tumor-destructive. Having received FDA clearance for its Investigational New Drug (IND) application, BDC-3042 is set to enter Phase 1 trials.
Bolt's pipeline also includes multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies, further validating its platform technology. The company’s financial health is robust, with strategic plans to fund ongoing and future clinical programs.
For more information, visit Bolt Biotherapeutics, Inc. website.
Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.
Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.
FAQ
What is Bolt Biotherapeutics, Inc.?
What is the Boltbody™ ISAC platform?
What are BDC-1001 and BDC-3042?
What recent achievements has Bolt Biotherapeutics made?
Who backs Bolt Biotherapeutics?
What is the significance of Orphan Drug Designation for BDC-1001?
What are the goals of the BDC-3042 program?
What partnerships does Bolt Biotherapeutics have?
How is Bolt Biotherapeutics advancing its clinical programs?
Where can I find more information about Bolt Biotherapeutics?
